In the fiercely competitive world of biopharma, the difference between winning and losing contracts often hinges on one critical factor: timing. As the industry navigates a landscape marked by patent cliffs, blockbuster drug expirations, and relentless…
In the high-stakes world of pharmaceuticals, timing is everything. As drug patent expirations approach, companies face a critical window to optimize their market strategies, maximize revenue, and prepare for generic competition. But tracking patent exp…
Track Global Drug Patent Expiry by Geography — Without Hiring a Team of Analysts Read Post »
Is Your Oncology Sales Pipeline at Risk? How the Patent Cliff Could Be Your Wake-Up Call—and Your Opportunity
In the rapidly evolving landscape of oncology treatments, the expiration of key patents—commonly known as the “patent cliff”—poses a significa…
The Patent Cliff Is Coming—Are You Ready to Seize the Biosimilar First-Mover Advantage?
In the high-stakes world of biopharmaceuticals, timing is everything. As blockbuster biologics approach patent expiry, the industry faces a seismic shift—one that c…
The $200 Billion Battle Over Bioequivalence: How the Fight to Prove ‘Sameness’ Is Reshaping the Future of Generic Drugs
Imagine a world where the cost of life-saving medications drops dramatically, where innovation isn’t stifled by regulatory ambiguity…
Prove It’s the Same: The $200 Billion Bioequivalence Fight Reshaping Generic Drugs Read Post »
In the high-stakes world of pharmaceutical innovation, the path from lab bench to pharmacy shelf is fraught with complexity, cost, and uncertainty. Yet, amid these challenges, a strategic legal pathway—Section 505(b)(2) of the Federal Food, Drug, and C…
The IRA Price Reset: A Game-Changer for Pharma Pricing — What It Means for Industry and Innovation
In the high-stakes world of pharmaceutical pricing, recent policy shifts are sending shockwaves through the industry. The Inflation Reduction Act (IRA) h…
The IRA Price Reset: What It Actually Does to Pharma Pricing, and What Comes Next Read Post »
The Patent Wall Is Crumbling: What Secondary Abandonment Means for the Future of Drug Innovation
In the relentless race to develop new medicines, pharmaceutical companies have long relied on a strategy known as "evergreening" — obtaining seco…
When the Patent Wall Crumbles: Secondary Abandonment and the Death of Drug Evergreening Read Post »
In the high-stakes world of pharmaceuticals, innovation alone isn’t enough. The real game-changer lies in how companies identify, secure, and leverage patent licensing opportunities to stay ahead of the curve—and the competition.
The Challenge: Naviga…
The Strategic Playbook for Identifying and Securing Drug Patent Licensing Opportunities Read Post »
In the relentless race to develop groundbreaking new medicines, the pharmaceutical industry often overlooks a powerful, underutilized strategy: drug repurposing. As highlighted in a compelling article by Drug Patent Watch, “No Patents, No Problem: The …
No Patents, No Problem: The Untapped Power of Drug Repurposing Read Post »
Get new actionable insights and updates from BiotechBlog
